Sangamo Biosciences Stock News

Morgan Stanley increased its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 24.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 891,147 shares of the biopharmaceutical companys stock after purchasing an additional 176,775 shares during the quarter. Morgan Stanleys holdings in Sangamo []

Metropolitan Life Insurance Co NY increased its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 108,530.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,848 shares of the biopharmaceutical companys stock after purchasing an additional 35,815 shares during the quarter. Metropolitan Life []

Wall Street analysts forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will announce sales of $29.15 million for the current quarter, Zacks reports. Four analysts have provided estimates for Sangamo Therapeutics earnings. The highest sales estimate is $32.00 million and the lowest is $28.00 million. Sangamo Therapeutics posted sales of $25.80 million during the same quarter last []

Amalgamated Bank boosted its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 32.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,611 shares of the biopharmaceutical companys stock after acquiring an additional 5,247 shares during the quarter. Amalgamated Banks holdings in Sangamo Therapeutics []

Sangamo Therapeutics Inc. (NASDAQ:SGMO) price on Thursday, November 18, fall -2.10% below its previous days close as a downside momentum from buyers pushed the stocks value to $9.32. A look at the stocks price movement, the close in the last trading session was $9.52, moving within a range at $9.265 and $9.67. The beta value Honey At Sangamo Therapeutics Inc. (SGMO) Is Worth Your Money Read More »

Wall Street brokerages forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will post sales of $29.15 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Sangamo Therapeutics earnings, with the lowest sales estimate coming in at $28.00 million and the highest estimate coming in at $32.00 million. Sangamo Therapeutics posted sales []

The mean of analysts' price targets for Sangamo (SGMO) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene therapy candidate for Fabry disease.  A

Sangamo Therapeutics' (SGMO) CEO Sandy Macrae on Q3 2021 Results - Earnings Call Transcript

Sangamo (SGMO) delivered earnings and revenue surprises of 2.94% and 5.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial

Sangamo has transitioned to what they called Wave 2 a couple years ago. Biogen and Novartis have partnered with Sangamo to pursue gene regulation. These partnerships are actively being grown with two

Sangamo Therapeutics: Finding An Opportunity To Reload

Our indicative theme of Gene Editing stocks has returned about 11% year-to-date, compared to the S&P 500 which is up by about 19% over the same period. However, the gains have overwhelmingly come from